Reviewed by Michael Gill, B. Sc.
6 Premature Ovarian Failure Clinical Trials Near Me
Top Hospitals for Premature Ovarian Failure Clinical Trials
Image of Center For Human Reproduction in New York.
Center For Human Reproduction
New York
2Active Trials
2All Time Trials for Premature Ovarian Failure
2012First Premature Ovarian Failure Trial
Image of Reproductive Medicine Associates of New Jersey in New Jersey.
Reproductive Medicine Associates of New Jersey
Basking Ridge
1Active Trials
1All Time Trials for Premature Ovarian Failure
2020First Premature Ovarian Failure Trial
Top Cities for Premature Ovarian Failure Clinical Trials
Image of New York in New York.
New York
2Active Trials
Center For Human ReproductionTop Active Site
Image of Basking Ridge in New Jersey.
Basking Ridge
1Active Trials
Reproductive Medicine Associates of New JerseyTop Active Site
Premature Ovarian Failure Clinical Trials by Phase of Trial
Phase 1 & 2 Premature Ovarian Failure Clinical Trials
1Active Premature Ovarian Failure Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Premature Ovarian Failure Clinical Trials by Age Group
18+ Premature Ovarian Failure Clinical Trials
1Active Premature Ovarian Failure Clinical Trials
Top Treatments for Premature Ovarian Failure Clinical Trials
Treatment Name
Active Premature Ovarian Failure Clinical Trials
All Time Trials for Premature Ovarian Failure
First Recorded Premature Ovarian Failure Trial
intra-ovarian platelet rich plasma injection
1
1
2020
Nitrate supplementation
1
1
2018
Transdermal Estrogen
1
1
2018
A-PRP
1
1
2018
Ovarian tissue transplant
1
1
2021

What Are Premature Ovarian Failure Clinical Trials?

Premature Ovarian Failure, more aptly called Primary Ovarian Insufficiency (POI), is a condition where a woman’s ovaries lose their normal functioning before the age of 40. The affected ovaries do not release eggs regularly or produce typical amounts of estrogen, often leading to infertility.

Premature Ovarian Failure clinical trials are tests for new and more advanced drugs and treatment approaches to lessen the impact, alleviate symptoms, and help more women retain their fertility.

Why Is Premature Ovarian Failure Being Studied Through Clinical Trials?

About 5% to 10% of women affected by this ovarian insufficiency get pregnant without any medical intervention, a phenomenon called spontaneous remission. Several others are able to conceive with treatment.

With premature ovarian failure clinical trials, researchers are looking for ways (drugs and treatments) to artificially induce remission and increase the successful treatment percentage so more women can retain their fertility and, if they want, conceive and give birth safely. The trials also help find more effective treatments for symptoms, make the condition more manageable, and retain/improve the quality of life by preventing or reducing the risk of other health conditions that ovarian insufficiency may cause.

What Are The Types of Treatments Available For Premature Ovarian Failure?

Currently, there’s no proven treatment for restoring the ovaries’ normal function. But there are ways to improve symptoms of premature ovarian failure, lower health risks, and help improve the odds of conceiving. Some of the treatments used for premature ovarian failure include:

  • Hormone replacement therapy
  • In-vitro fertilization
  • Calcium and vitamin D supplements
  • Healthy weight maintenance
  • Regular physical activity

What Are Some Recent Breakthrough Clinical Trials For Premature Ovarian Failure?

2021: A literature review conducted by Chinese researchers found that mesenchymal stem cell (MSC) therapy can have curative effects for premature ovarian failure. The study evaluated MSCs taken from different sources and found them all equally effective in the treatment. MSC therapy, the researchers concluded, could be a viable treatment option for premature ovarian failure and may even help restore the lost reproductive function.

2021: An animal study conducted by Chinese researchers found a TCM formula – Hy yang yang kun (Hyyk) – to have protective effects on ovarian function in premature ovarian insufficiency. The drug is found to work by promoting the development of follicles, providing evidence for the drug to likely emerge as an alternative treatment for premature ovarian failure.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Premature Ovarian Failure Clinical Trial Research?

NICHD: The government organization that falls under the US Department of Health and Human Services is actively conducting and supporting epidemiological studies, lab research projects, and clinical trials to understand, prevent, and treat primary ovarian insufficiency and its associated health conditions.

Society for Women’s Health Research: SWHR is a Washington-based NGO working to transform women’s health through research, advocacy, and education.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009 Feb 5;360(6):606-14. doi: 10.1056/NEJMcp0808697. Review. https://pubmed.ncbi.nlm.nih.gov/191966772 Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014 Jul;124(1):193-197. doi: 10.1097/01.AOG.0000451757.51964.98. https://pubmed.ncbi.nlm.nih.gov/249454563 Gordon CM, Kanaoka T, Nelson LM. Update on primary ovarian insufficiency in adolescents. Curr Opin Pediatr. 2015 Aug;27(4):511-9. doi: 10.1097/MOP.0000000000000236. Review. https://pubmed.ncbi.nlm.nih.gov/260874264 Gordon CM, Zemel BS, Wren TA, Leonard MB, Bachrach LK, Rauch F, Gilsanz V, Rosen CJ, Winer KK. The Determinants of Peak Bone Mass. J Pediatr. 2017 Jan;180:261-269. doi: 10.1016/j.jpeds.2016.09.056. Epub 2016 Nov 3. https://pubmed.ncbi.nlm.nih.gov/278162195 Bakhsh H, Dei M, Bucciantini S, Balzi D, Bruni V. Premature ovarian insufficiency in young girls: repercussions on uterine volume and bone mineral density. Gynecol Endocrinol. 2015 Jan;31(1):65-9. doi: 10.3109/09513590.2014.958987. Epub 2014 Sep 9. https://pubmed.ncbi.nlm.nih.gov/252031446 Sadeghi MR. New hopes for the treatment of primary ovarian insufficiency/premature ovarian failure. J Reprod Infertil. 2013 Jan;14(1):1-2. https://pubmed.ncbi.nlm.nih.gov/239265537 Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009 Jul;94(7):2277-83. doi: 10.1210/jc.2008-1878. Epub 2009 Apr 28. https://pubmed.ncbi.nlm.nih.gov/19401379